Actinium to present three abstracts at SOHO 2023

2020 07 23 21 58 4280 Cancer Radiotherapy 400

Radiotherapy developer Actinium Pharmaceuticals will present three abstracts accepted for poster presentation at the Society of Hematologic Oncology (SOHO) 2023 annual meeting in Houston, TX, between September 6 and 9.

Presentations will include the following:

  • "The Randomized Phase III SIERRA (Study of Iomab-B in Elderly Relapsed or Refractory AML) Trial: Successful Allogeneic Hematopoietic Stem Cell Transplantation Using Treatment With Iomab-B-Led Regimen for Patients With Active, Relapsed or Refractory AML With Failed Targeted Therapies"
  • "Sequential Salvage Chemotherapy and Lintuzumab-Ac225 in Relapsed/Refractory AML Results in Deep Responses and Prolonged Survival in Adverse Risk Acute Myeloid Leukemia (AML) and in AML Patients that Received Prior Venetoclax Therapy," and "Antileukemic Activity of Lintuzumab-Ac225 in Preclinical Model of FLT3 Mutant AML."
Page 1 of 434
Next Page